Biogen-Eisai’s potential Aduhelm sequel drug granted speedy review by FDA
Biogen-Eisai’s potential Aduhelm sequel drug granted speedy review by FDA [...]
Editor’s Corner: Fierce Biotech’s top 10 most read stories in 2021
Editor’s Corner: Fierce Biotech’s top 10 most read stories in [...]
Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree
Novartis inks $800M upfront buyout of Gyroscope to continue eye [...]
Aiming to make 70 the new 50, Korify rolls out $100M longevity and mental health venture fund
Aiming to make 70 the new 50, Korify rolls out [...]
PhaseBio blames COVID-19 disruption as cardiovascular study axed
PhaseBio blames COVID-19 disruption as cardiovascular study axed aarmstrong Tue, [...]
Pfizer reports patient death in early-stage Duchenne gene therapy trial, halts enrollment
Pfizer reports patient death in early-stage Duchenne gene therapy trial, [...]
Abandoned by Amgen, Cytokinetics lands deal for Chinese rights to heart failure prospect
Abandoned by Amgen, Cytokinetics lands deal for Chinese rights to [...]
Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospect
Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese [...]
Sanofi gambles $1B upfront on preclinical oncology biotech, bagging Amunix for its pipeline of T-cell engagers
Sanofi gambles $1B upfront on preclinical oncology biotech, bagging Amunix [...]
Chutes & Ladders—CRISPR Therapeutics bids adieu to R&D head in securities filing
Chutes & Ladders—CRISPR Therapeutics bids adieu to R&D head in [...]